Antifibrinolytic Drugs: Tranexamic Acid, Uses, Safety & Clinical Monitoring
On this page
1. Fibrinolysis and the drug target
Once a fibrin clot has stopped bleeding, fibrinolysis removes it: tPA (and urokinase) convert plasminogen to plasmin, and plasmin digests fibrin (and, if unchecked, fibrinogen). This is normally protective. When fibrinolysis is premature or excessive — trauma, childbirth, surgery — bleeding worsens and an antifibrinolytic can stabilise the clot.
Scroll the table sideways on a smaller screen.
| Component | Function | Drug relevance |
|---|---|---|
| tPA / uPA | Convert plasminogen → plasmin on the fibrin surface | Lysine analogues (TXA, aminocaproic acid) competitively block plasminogen's lysine-binding site so it cannot attach to fibrin |
| Plasmin | Degrades fibrin (clot dissolution) | Blockade preserves clot stability |
| α₂-antiplasmin, PAI-1 | Natural brakes on fibrinolysis | Antifibrinolytics reinforce this brake; excessive inhibition tips toward thrombosis |
| Thrombolytics (streptokinase, alteplase) | Accelerate plasmin generation to dissolve pathological clots | The opposite therapeutic direction — never confuse the two classes |
2. Classification and pharmacology
Scroll the table sideways on a smaller screen.
| Drug | Mechanism | Notes |
|---|---|---|
| Tranexamic acid (TXA) | Synthetic lysine analogue; competitively blocks lysine-binding sites on plasminogen/plasmin, preventing fibrin binding and plasmin formation | Main agent in use; oral, IV and topical routes |
| Aminocaproic acid | Lysine analogue with similar inhibition | Specialist perioperative/haematology use; e.g., 4–5 g IV load then 1 g/hour infusion in protocols |
| Aprotinin | Serine-protease inhibitor (inhibits plasmin directly) | Restricted use (cardiac surgery); hypersensitivity and safety concerns limit it |
3. Tranexamic acid in detail
Scroll the table sideways on a smaller screen.
| Aspect | Detail |
|---|---|
| Adult dosing (indication-specific) | PPH: 1 g IV over 10 min as soon as possible (within 3 h of birth), then 1 g IV over 8 h if bleeding continues. Trauma (CRASH-2): 1 g over 10 min within 3 h of injury, then 1 g over 8 h. Heavy menstrual bleeding: 1 g orally TDS–QDS (up to 4 days/cycle). Surgery: per protocol, often 1 g IV pre-incision. Topical (mouthwash 4.8–5%) for oral bleeding/dental extraction in anticoagulated patients. |
| Paediatric dosing | Specialist-protocol only; common teaching range 15–30 mg/kg IV loading (max 1 g) then maintenance per protocol. Never extrapolate adult emergency doses without senior direction. |
| Pharmacokinetics | Rapid renal excretion, mostly unchanged — half-life rises sharply in renal impairment → dose-adjust by protocol; crosses placenta and appears in breast milk in small amounts (compatible with breastfeeding). |
| Indications | PPH (WHO-recommended); trauma with significant bleeding; surgical blood-loss reduction; heavy menstrual bleeding (non-hormonal option); dental/mucosal bleeding adjunct in haemophilia; epistaxis topical. |
| Adverse effects | Nausea, vomiting, diarrhoea, dizziness, headache; rapid IV push → hypotension; colour-vision disturbance; seizures reported with high-dose IV use (neurosurgical/cardiac settings); thrombosis risk if misused. |
| Contraindications | Active thromboembolic disease (DVT/PE/arterial thrombus); acquired defective colour vision (for prolonged use); subarachnoid haemorrhage (cerebral oedema/ischaemia risk — older concern); undifferentiated upper-urinary-tract haematuria (risk of clot colic/obstruction); severe renal impairment without dose adjustment; known hypersensitivity. Caution: prior thrombosis history, combined hormonal contraceptive use (additive thrombosis risk — for non-emergency indications review together). |
| Interactions | Additive pro-thrombotic effect with oestrogen-containing contraceptives or thrombogenic medicines — relevant for elective (non-emergency) prescribing; minimal CYP interactions (renally cleared, low protein binding). |
| Counselling | For heavy periods: take only during menstruation; reduces bleeding but does not treat the cause — keep review appointments, check iron/ferritin; report leg swelling, chest pain, breathlessness, visual changes immediately; seek urgent care for uncontrolled bleeding. |
4. Indications and dosing
Scroll the table sideways on a smaller screen.
| Situation | Typical regimen | Clinical rule |
|---|---|---|
| Postpartum haemorrhage | 1 g IV over 10 min (within 3 h), then 1 g over 8 h if needed | Alongside uterine massage, uterotonics, fluids, source control — never instead of them |
| Major trauma | Same 1 g + 1 g over 8 h regimen, within 3 h of injury | Record injury time; adjunct to ABCDE, blood products, surgery |
| Surgery | 1 g IV pre-incision (protocol-dependent) | Review thrombosis history and renal function first |
| Heavy menstrual bleeding | 1 g PO TDS–QDS during menses, max 4 days/cycle | Assess cause, check iron; review CHC/thrombosis risk |
| Dental/mucosal bleeding (haemophilia, anticoagulation) | Topical 4.8–5% mouthwash; systemic per haematology protocol | Adjunct to factor replacement and local measures |
| Epistaxis | Topical (soaked pledget) as adjunct | Pressure and packing remain first-line |
4.1 Where TXA sits in the major-haemorrhage bundle
TXA never acts alone. A structured major-haemorrhage response typically runs:
- Call for help early — activate the emergency/major-haemorrhage pathway.
- Airway, breathing, circulation — two wide-bore cannulas, bloods (FBC, clotting, fibrinogen, crossmatch), begin balanced transfusion per protocol.
- TXA early — 1 g over 10 min then 1 g over 8 h (within 3 h windows for trauma/PPH).
- Source control — surgery, interventional radiology, packing, uterotonics as appropriate.
- Correct the lethal triad — hypothermia, acidosis, coagulopathy: warm the patient, correct Ca²⁺, replace fibrinogen (cryoprecipitate/fibrinogen concentrate per protocol).
- Monitor and reassess — physiological response, ongoing losses, urine output; escalate if the trajectory is not improving.
4.2 Dental example — anticoagulated patient needing extraction
A patient on warfarin (INR in range) needs a tooth extraction with a history of post-extraction bleeding. The haematology/dental protocol commonly combines: local measures first (atraumatic technique, sutures, haemostatic gauze, pressure), topical TXA mouthwash (4.8–5%) used 4×/day for several days, and only where bleeding risk is high, systemic TXA — while continuing monitoring of the INR. The lesson: antifibrinolytics are adjuncts layered onto local haemostasis, not replacements for it.
5. Safety, contraindications and monitoring
- Pre-treatment checklist: source and mechanism of bleeding; time of onset (PPH/trauma windows); thrombosis history and thrombophilia; seizure history; renal function; anticoagulants/antiplatelets; pregnancy/breastfeeding for elective use.
- Monitor during acute use: pulse, BP, ongoing losses, urine output, mental state, response to definitive treatment; trend FBC, coagulation/fibrinogen and renal function per major-haemorrhage protocol. A single lab value does not prove haemostasis.
- Administration: give IV TXA at the prescribed rate (over ~10 min) — rapid push causes hypotension.
- Escalate immediately for: chest pain, dyspnoea, new unilateral leg swelling, focal neurology, visual disturbance, or persistent/severe bleeding.
6. Worked scenarios
Scenario A — PPH: 40 minutes after a vaginal delivery, a mother bleeds heavily with a relaxed uterus. Call for help; rub up a contraction; give oxytocin; 1 g TXA IV over 10 min; two large-bore IV lines, fluids; examine for tears/retained placenta; continue 1 g over 8 h if bleeding persists; escalate to balloon tamponade/theatre as needed. TXA is one element of a bundle — speed matters.
Scenario B — trauma: a boda-boda rider, GCS 14, BP 90/60, 90 minutes after a crash. Activate major haemorrhage pathway: ABCDE, two wide-bore cannulas, bloods including crossmatch, 1 g TXA over 10 min then 1 g over 8 h (within the 3-hour window), tranexamic timing documented, damage-control surgery referral.
Scenario C — heavy periods with prior PE: 34-year-old requests TXA for heavy menses; history of unprovoked PE on anticoagulation 3 years ago. Do not prescribe casually: assess thrombosis risk, review CHC use, consider alternatives (levonorgestrel IUD, hormonal therapy); if TXA is used, specialist review and the lowest effective dose with clear safety-netting.
7. Key points
References
- WOMAN Trial Collaborators. "Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage." Lancet 2017. (Library reference.)
- CRASH-2 Trial Collaborators. "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients." Lancet 2010. (Library reference.)
- WHO — recommendation on tranexamic acid for the treatment of postpartum haemorrhage (2017 update). (Library reference.)
- NICE NG88 — Heavy menstrual bleeding: assessment and management. (Library reference.)
For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.